Platelet Cyclooxygenase Expression in Normal Dogs

Journal of Veterinary Internal Medicine

Volumn 25, Issue 5, 2011, Pages 1106-1112

  Thomason, J ^a   Lunsford, K ^a   Mullins, K ^a   Stokes, J ^a   Pinchuk, L ^a   Wills, R ^a   Mclaughlin, R ^a   Langston, C ^a   Pruett, S ^a   Mackin, A ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Aspirin; Canine; Cyclooxygenase

Indexed keywords

11 DEHYDRO THROMBOXANE B2; 11-DEHYDRO-THROMBOXANE B2; ACETYLSALICYLIC ACID; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUG DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE B2;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOSYNTHESIS; BLOOD; DOG; DRUG EFFECT; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; METABOLISM; THROMBOCYTE; URINE;

ANIMALS; ASPIRIN; BLOOD PLATELETS; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOGS; FEMALE; FLOW CYTOMETRY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOXANE B2;

ANIMALIA; CANIS FAMILIARIS;

EID: 80053056704     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.00781.x     Document Type: Article

References (44)

1. Guthikonda S, Lev E, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007;5:490-496.
2. Rocca B, FitzGerald G. Cyclooxygenase and prostaglandins: Shaping up the immune response. Int Immunopharmacol 2002;2:603-630.
3. Bjorkman D. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 1998;105:8S-12S.
4. Munoz J, Navarro C, Noriega V, et al. Synergism between COX-3 inhibitors in two animal models of pain. Inflammopharmacol 2010;18:65-71.
5. Simmons D. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 2003;110:265-268.
6. Tanaka N, Sato T, Fujita H, et al. Constitutive expression and involvement of cyclooxygenase-2 in human megakaryocytopoiesis. Arterioscler Thromb Vasc Biol 2004;24:607-612.
7. Kay-Mugford P, Benn S, LaMarre J, et al. Cyclooxygenase expression in canine platelets and Mardin-Darby canine kidney cells. Am J Vet Res 2000;61:1512-1516.
8. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634-7639.
9. Bergh M, Budsberg S. The Coxib NSAIDs: Potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 2005;19:633-643.
10. Dixon D, Kaplan C, McIntyre T, et al. Post-transcriptional control of cyclooxygenase-2 gene expression. J Biol Chem 2000;275:11750-11757.
11. Weber A, Przytulski B, Schumacher M, et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: Induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002;117:424-426.
12. 2. J Biol Chem 2001;276:34918-34927.
13. Yu Y, Cheng Y, Fan J, et al. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest 2005;115:986-995.
14. Zetterberg E, Lundberg L, Palmblad J. Expression of COX-2, TIE-2 and glycodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythaemia vera. Br J Haematol 2003;121:497-499.
15. Patrono C, Dalen J, Fuster V, et al. Platelet-active drugs. Chest 2001;119:39S-63S.
16. Mroske C, Plant M, Franks D, et al. Characterization of prostaglandin endoperoxide H synthase-1 enzyme expression during differentiation of the megakaryocytic cell line MEG-01. Exp Hematol 2000;28:411-421.
17. Alagha A, Moman E, Adamo M, et al. Design, synthesis and evaluation of aspirin analogues having an additional carboxylate substituent for antithrombotic activity. Bioorg Med Chem Lett 2009;19:4213-4216.
18. Assadian A, Lax J, Meixner-Loicht U, et al. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: Flow cytometric measurement of aspirin-induced platelet inhibition. J Vasc Surg 2007;45:1142-1147.
19. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: A comprehensive systemic review. Br J Clin Pharmacol 2008;66:222-232.
20. Kour D, Tandon V, Kapoor B, et al. Aspirin resistance. New Horiz 2006;8:116-117.
21. Wilson J, Chandrasekharan N, Westover K, et al. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 2004;65:810-818.
22. Mischke R, Keidel A. Influence of platelet count, acetylsalicylic acid, von Willebrand's disease, coagulopathies, and haematocrit on results obtained using a platelet function analyser in dogs. Vet J 2003;165:43-52.
23. Nielsen L, Zois N, Pedersen H, et al. Platelet function in dogs: Breed differences and effect of acetylsalicylic acid administration. Vet Clin Pathol 2007;36:267-273.
24. Morales F, Couto C, Iazbik M. Effects of 2 concentrations of sodium citrate on coagulation test results, von Willebrand factor concentration, and platelet function in dogs. J Vet Intern Med 2007;21:472-475.
25. 2 excretion in dogs with gastric dilatation-volvulus. Am J Vet Res 2006;67:78-83.
26. 2 and coagulation activation markers measured within 24 h of human acute ischemic stroke. Neurosci Lett 2001;313:88-92.
27. Booyse FM, Rafelson ME Jr. Stable messenger RNA in the synthesis of contractile protein in human platelets. Biochim Biophys Acta 1967;145:188-190.
28. Brogren H, Karlsson L, Anderson M, et al. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004;104:3943-3948.
29. Ueda N, Yamashita R, Yamamoto S, et al. Induction of cyclooxygenase-1 in a human megakaryoblastic cell line (CMK) differentiated by phorbol ester. Biochim Biophys Acta 1997;1344:103-110.
30. DeLong C, Smith W. An intronic enhancer regulates cyclooxygenase-1 gene expression. Biochem Biophys Res Commun 2005;338:53-61.
31. Tomlinson J, Wilder O, Young K, et al. Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. Am J Vet Res 2004;65:761-769.
32. Bhandari P, Bateman A, Mehta R, et al. Mucosal expression of cyclooxygenase isoforms 1 and 2 is increased with worsening damage to the gastric mucosa. Histopathology 2005;46:280-286.
33. Hoffmann U, Banas B, Kruger B, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human renal allograft rejection - a prospective study. Transpl Int 2006;19:203-212.
34. Dore M, Cote L, Mitchell A, et al. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J Histochem Cytochem 1998;46:77-84.
35. Gupta R, Tejada L, Tong B, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003;63:906-911.
36. Jones CJ, Budsberg SC. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc 2000;217:721-729.
37. Reilly IAG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186.
38. Perneby C, Granstrom E, Beck O, et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: Comparison with GC-MS. Thromb Res 1999;96:427-436.
39. Censarek P, Steger G, Paolini C. Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting. Thromb Haemost 2007;98:1309-1315.
40. Martin C, Talbert R. Aspirin resistance: An evaluation of current evidence and measurement methods. Pharmacotherapy 2005;25:942-953.
41. Frelinger A, Furman M, Linden M, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1 - and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation 2006;113:2888-2896.
42. Vejar M, Fragasso G, Hackett D, et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990;63:163-168.
43. Zimmerman G, Weyrich A. Signal-dependent protein synthesis by activated platelets new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008;28:s17-s24.
44. Weinkle T, Center S, Randolph J, et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 2005;226:1869-1880.